Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
5,489 people get AMGN articles and Market Currents by email alert.
Get email alerts on AMGN »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
PR Newswire (Thu, 4:18PM)
-
-
PR Newswire (Wed, 6:00PM)
-
-
-
-
-
-
-
PR Newswire (May 9, 2013)
-
-
-
After AbbVie's Humira: What Next?Peter Geschek • Mon, May 6 -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Why Amgen Still Has Valuation Upside RemainingValuentum • Fri, Feb 15 -
-
Is Amgen Running Out Of Steam In 2013?StockRiters • Tue, Jan 22 -
-
-
-
-
-
-
Amgen Management Discusses Q3 2012 Results - Earnings Call TranscriptTue, Oct 23, 2012
-
Amgen Management Discusses Q2 2012 Results - Earnings Call TranscriptThu, Jul 26, 2012
-
Amgen's CEO Discusses Q1 2012 Results - Earnings Call TranscriptTue, Apr 24, 2012
-
Amgen's CEO Discusses Q4 2011 Results - Earnings Call TranscriptThu, Jan 26, 2012
-
Amgen's CEO Discusses Q3 2011 Results - Earnings Call TranscriptMon, Oct 24, 2011
-
Amgen's CEO Discusses Q2 2011 Results - Earnings Call TranscriptFri, Jul 29, 2011
-
Amgen's CEO Discusses Q1 2011 Results - Earnings Call TranscriptWed, Apr 20, 2011
-
Amgen's CEO Discusses Q4 2010 Results - Earnings Call TranscriptTue, Jan 25, 2011
-
Amgen Management Discusses Q3 2010 Results - Earnings Call TranscriptTue, Oct 26, 2010
-
Amgen Q2 2010 Earnings Call TranscriptFri, Jul 30, 2010
-
Amgen Inc. Q1 2010 Earnings Call TranscriptThu, Apr 22, 2010
-
Amgen, Inc. Q4 2009 Earnings Call TranscriptMon, Jan 25, 2010
-
Amgen, Inc. Q3 2009 Earnings Call TranscriptWed, Oct 21, 2009
-
Amgen, Inc. Q2 2009 Earnings Call TranscriptTue, Jul 28, 2009
-
Amgen Inc., F1Q09Earnings Call TranscriptThu, Apr 23, 2009
-
Amgen Inc. Q4 2008 Earnings Call TranscriptTue, Jan 27, 2009
-
PR Newswire (Thu, 4:18PM)
-
PR Newswire (Wed, 6:00PM)
-
PR Newswire (May 9, 2013)
-
at CNBC.com (May 1, 2013)
-
at CNBC.com (Apr 26, 2013)
-
at MarketWatch.com (Apr 26, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at MarketWatch.com (Apr 24, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at CNBC.com (Apr 23, 2013)
-
at CNBC.com (Apr 23, 2013)
-
at CNBC.com (Apr 23, 2013)
-
at MarketWatch.com (Apr 23, 2013)
-
at MarketWatch.com (Apr 21, 2013)
AMGN vs. ETF Alternatives
Company Description
Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” and “us”) is the world’s largest independent biotechnology medicines company. We discover, develop, manufacture and market medicines for grievous illnesses. We focus solely on human therapeutics and... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, July 26, 2012, 5:17 PM Sometimes hindsight may not always be such a wonderful thing, especially for Human Genome Sciences (HGSI). The drug developer, which agreed to be bought by GlaxoSmithKline (GSK) earlier this month for $14.25 per share, says it received and rejected a much higher $35 per share takeover bid by Amgen (AMGN) back in August, 2010. It decided not to sell at the time because regulatory approval for its lupus drug Benlystsa was expected later that year. Ah, if only... 1 Comment [Healthcare, M&A, Global & FX]
- Thursday, July 26, 2012, 4:29 PM More on Amgen (AMGN): Q2 beats across the board on a 13% Y/Y jump in total revenue. Product sales growth was driven by strong performance across the portfolio. Xgeva sales total: $179M. For 2012, the company guides higher, now seeing an EPS of $6.20 to $6.35 on revenue of $16.9B to $17.2B. Street estimates are for earnings of $6.15 per share on $16.37B in revenue. Shares +4.4% AH. Comment! [Healthcare, Earnings, On the Move]
- Thursday, July 26, 2012, 4:11 PM Amgen (AMGN): Q2 EPS of $1.61 beats by $0.07. Revenue of $4.48B (+13% Y/Y) beats by $400M. Shares +3.4% AH. (PR) Comment! [Earnings, Healthcare, On the Move]
- Thursday, July 26, 2012, 12:10 AM Notable earnings after Thursday's close: AMGN, AMZN, APKT, ARBA, CA, CB, CBL, CERN, CINF, CLWR, CSTR, DECK, EXPE, FB, FBHS, GILD, HGSI, IM, INFA, KEG, KLAC, LEG, MCK, MXIM, PFG, QLGC, QLIK, RGC, RSG, SBUX, SPF, TLAB, UHS, VRSN Comment! [Earnings]
- Wednesday, July 25, 2012, 5:35 PM Notable earnings after Thursday's close: AMGN, AMZN, APKT, ARBA, CA, CB, CBL, CERN, CINF, CLWR, CSTR, DECK, EXPE, FB, FBHS, GILD, HGSI, IM, INFA, KEG, KLAC, LEG, MCK, MXIM, PFG, QLGC, QLIK, RGC, RSG, SBUX, SPF, TLAB, UHS, VRSN Comment! [Earnings]
- Thursday, July 19, 2012, 6:06 PM Amgen (AMGN) declares $0.36/share quarterly dividend, in line with previous. Forward yield 1.8%. For shareholders of record Aug 16. Payable Sep 07. Ex-div date Aug 14. (PR) Comment! [Dividends]
- Monday, July 16, 2012, 10:39 AM Amgen (AMGN +0.3%) bucks a weak tape on positive comments out of Baird this morning ahead of its Q2 report. The firm says it's anticipating the company to beat expectations, citing its strong operational upside and insulation from weak macro conditions. Stock momentum should also be aided by additional stockholder incentives such as dividend raises and buybacks, and it raises its price target to $79 from $75. Comment! [Healthcare]
- Wednesday, June 20, 2012, 5:06 PM West Pharmaceutical Services (WST) announces an agreement with Amgen (AMGN) to evaluate Daikyo Crystal Zenith technologies for drug containment. The technology was developed by West's partner, Daikyo Seiko. No further details of the agreement were disclosed. Comment!
- Thursday, May 17, 2012, 11:05 AM GSK, J&J (JNJ) and Amgen (AMGN) yesterday released positive results from small trials of cancer drugs ahead of a big industry meeting in early June. GSK combined two melanoma medicines, JNJ's already approve Zytiga helped eliminate prostate cancer that hadn't yet spread, and Amgen has revived the once discarded rilotumumab for treating gastric cancer. Comment! [Healthcare]
- Friday, April 27, 2012, 4:04 AM The FDA rejects Amgen's (AMGN) application to expand the use of the drug Xgeva to delay the spread of tumors to the bone in patients suffering from advanced prostate cancer. It's a blow for Amgen, as analysts see Xgeva and a related osteoporosis drug Prolia as among the most important growth drivers for the company. Comment! [Healthcare]
- Wednesday, April 25, 2012, 8:14 AM Amgen (AMGN) agrees to buy 95.6% of privately-held Turkish company Mustafa Nevzat Pharmaceuticals for an amount that values the firm at $700M. The acquisition will help AMGN expand its operations in the fast-growing Turkish market and surrounding region (also: earnings). AMGN +1.3% premarket. Comment! [Healthcare, M&A]
- Tuesday, April 24, 2012, 5:11 PM More on Amgen (AMGN): Q1 beats across the board on strong sales growth and better margins. Combined sales of Neulasta and Neupogen +9%, Xgeva +14%, and Prolia +9%. Operating margins rose to 36.4% from 34.9%. Comment! [Healthcare, Earnings]
- Tuesday, April 24, 2012, 4:13 PM Amgen (AMGN): Q1 EPS of $1.61 beats by $0.16. Revenue of $4.05B (+9% Y/Y) beats by $120M. (PR) Comment! [Earnings, Healthcare]
- Tuesday, April 10, 2012, 8:52 AM Amgen (AMGN) acquires privately-held KAI Pharmaceuticals for $315M in a deal that will give it widespread rights for kidney disease treatment KAI-4169. As part of the agreement between the firms, Amgen has provided a loan to enable Phase 3 clinical development planning for KAI-4169 prior to the transaction closing. Comment! [M&A, Healthcare]
- Monday, April 2, 2012, 4:39 PM Amgen (AMGN) and AstraZeneca (AZN) have agreed to collaborate on the development and commercialization of 5 drugs in Amgen's clinical inflammation porfolio. AstraZeneca will lead the way in developing 3 of the 5 drugs. AstraZeneca will make a $50M one-time payment to Amgen, as well as royalty payments following commercialization. 1 Comment [Healthcare]
- Tuesday, March 27, 2012, 3:12 PM Affymax (AFFY +10.9%) shares resume trading, popping more than 10% after the company confirms the FDA cleared the company's peginesatide anemia treatment for patients on dialysis for chronic kidney disease. The drug will be AFFY's first marketed product. Competitor Amgen (AMGN +0.5%) also trades higher. Comment! [Healthcare, On the Move]
-
Jim Van Meerten
AMGN - 88% Barchart technical buy signal - 8 new highs and up 5.01% in the last month - Relative Strength Index 59.45% - View all 0 replies
-
- View all 0 replies
-
Jim Van Meerten
AMGN - 100% Barchart technical buy signal - 7 new highs and up 3.28% in the last month - Relative Strength Index 71.23% - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES